Group 1 - The third Tianjin Qihuang Forum and the first Guoyun Traditional Chinese Medicine Cultural Industry Innovation Development Summit opened on November 15, focusing on the theme of "inheritance, innovation, integration, and development" [1] - The event gathered over 200 participants, including academicians, masters of traditional Chinese medicine, scholars, industry experts, and representatives from the traditional Chinese medicine industry chain, promoting deep integration of traditional Chinese medicine and cultural industries [1][3] - The summit featured a three-dimensional model of "academic discussion + industry docking + cultural experience," aiming to inject new momentum into Tianjin's goal of becoming a leading domestic and internationally renowned city for traditional Chinese medicine [1] Group 2 - This year's forum uniquely combined the "Guoyun Traditional Chinese Medicine Cultural Industry Innovation Development Summit," focusing on innovation in the traditional Chinese medicine health industry and upgrading the industry chain, enhancing cross-industry integration and international dissemination [3] - A showcase of ten products, including medicinal food bread and special stamps, was held, with three products highlighted for promotion, attracting significant attention from attendees [3][5] - The forum included discussions on international pathways for promoting traditional Chinese culture, with a presentation by the Deputy Director of the Brand and Market Center of Tianjin Pharmaceutical Daren Tang Group, focusing on the brand's renewal and internationalization efforts [5][6] Group 3 - In a sub-forum on upgrading the traditional Chinese medicine industry chain, the Chief Information Officer of Tianjin Pharmaceutical Daren Tang Group presented on the company's digital transformation and AI strategies, showcasing the results of their AI practices and data innovation since the transformation [8][9]

Core Insights - The integration of technology and traditional Chinese medicine (TCM) is gaining momentum, with significant developments in AI applications within the industry [1][2] - Guoshengtang is positioning itself as a leader in TCM modernization and internationalization, aiming to enhance the quality and accessibility of TCM resources [1][3] Group 1: AI and Technology Integration - Guoshengtang has established strategic partnerships with top research teams to develop TCM-specific AI models, marking a shift from exploration to large-scale application [2][3] - The AI platform, "Guoyi AI Avatar," has achieved an expert simulation consistency of over 86%, enhancing the efficiency of online consultations and addressing the uneven distribution of quality medical resources [3][4] - The company has been building a digital infrastructure since 2019, accumulating extensive clinical data to support its AI initiatives [2][3] Group 2: Clinical Research and Evidence-Based Medicine - The launch of the "Xunyan Zhizhi" clinical research integration platform aims to address the challenges of evidence-based evaluation in TCM, utilizing AI to create a comprehensive innovation system [6][7] - This platform will facilitate the collection of accurate clinical data, enabling objective assessments of TCM efficacy and promoting a shift from experience-based to evidence-based medicine [6][7] Group 3: Global Expansion and Market Strategy - Guoshengtang is expanding its global footprint through a "merger + cooperation + self-built" strategy, with plans to acquire 14 clinics in Singapore and establish a joint venture with a digital healthcare platform [9][10] - The company has formed strategic partnerships with various platforms to enhance its service accessibility and user engagement, significantly increasing its customer acquisition rates [8][9] - By 2026, Guoshengtang plans to enter markets in Hong Kong and Malaysia, followed by expansion into Europe and the United States [1][9]

Group 1 - The 2025 Changchun International Pharmaceutical and Health Industry Expo opened, featuring 41 enterprises from Hong Kong, Macau, Taiwan, and overseas Chinese communities showcasing health products and AI diagnostic equipment [1] - Exhibitors expressed a desire to establish closer cooperation with Jilin in the supply of ginseng and traditional Chinese medicine resources, highlighting Jilin's advantages in producing traditional medicine raw materials, particularly Changbai Mountain ginseng [1] - Companies like Shan Shen You Health Technology (Hong Kong) Co., Ltd. aim to leverage Jilin's raw material advantages to expand their product lines and increase production and sales scale, focusing primarily on the mainland market [1] Group 2 - The Taiwan Health Industry Alliance organized 17 enterprises focusing on biotechnology and health management, with companies like Meilian Biotechnology Co., Ltd. developing more efficient skin absorption products using nanotechnology [2] - Overseas Chinese enterprises are concentrating on supply chain stability and international market expansion, recognizing the growing global demand for traditional Chinese medicine [2] - The event serves as a platform for connecting raw material origins with markets, with hopes to promote deeper cooperation between Hong Kong, Macau, Taiwan enterprises and Jilin in the traditional medicine and ginseng industries [2]

Core Viewpoint - Yiling Pharmaceutical's innovative traditional Chinese medicine, Yangzheng Xiaojie Capsule, has been approved for sale in Thailand, marking a significant milestone in the company's internationalization strategy and highlighting the growing global recognition of traditional Chinese medicine in the oncology field [1][3]. Group 1: Product Approval and Significance - Yangzheng Xiaojie Capsule is the latest product from Yiling Pharmaceutical to receive registration in Thailand, following the success of Lianhua Qingwen Capsule, Shensong Yangxin Capsule, and Jinlidag Granules [1]. - The approval signifies the unique value of traditional Chinese medicine in cancer treatment is increasingly acknowledged internationally [1]. Group 2: Research and Efficacy - Joint research by Professor Jiang Wenguo from Cardiff University and Yiling Pharmaceutical found that Yangzheng Xiaojie Capsule significantly interferes with tumor cell invasion and metastasis by inhibiting the overactivation of the PI3K/Akt signaling pathway [2]. - Clinical studies led by Academician Yu Jinming showed that Yangzheng Xiaojie Capsule combined with chemotherapy significantly improved the quality of life for patients with advanced non-small cell lung cancer, with a clinical symptom improvement rate of 83.5% [2]. - Another study indicated that the combination of Yangzheng Xiaojie Capsule with interventional chemotherapy for primary liver cancer resulted in a total effective rate of 65.2%, significantly higher than the control group's 36.1% [2]. Group 3: Safety Profile - A meta-analysis involving 19 studies and 2,125 patients demonstrated that Yangzheng Xiaojie Capsule effectively alleviates gastrointestinal reactions caused by radiotherapy and chemotherapy, mitigates bone marrow suppression, and protects liver function, indicating good safety [3]. Group 4: Market Expansion - The approval of Yangzheng Xiaojie Capsule in Thailand is a vital step in Yiling Pharmaceutical's international strategy and serves as a practical example of traditional Chinese medicine contributing to the "Belt and Road" initiative [3]. - Yiling Pharmaceutical has successfully registered and launched 17 innovative traditional Chinese medicines in over 50 countries and regions worldwide [3].

Core Insights - Yangzheng Xiaojie Capsule is an innovative traditional Chinese medicine developed under the guidance of traditional Chinese medicine theory, targeting the pathological mechanisms of tumors and has been approved for use in primary liver cancer treatment in China [1][2] Group 1: Product Efficacy - Yangzheng Xiaojie Capsule integrates traditional methods with modern anti-cancer drugs, demonstrating a dual action of supporting the body while eliminating pathogens, which aligns with modern cancer treatment goals [1] - Clinical studies indicate that Yangzheng Xiaojie Capsule significantly improves the quality of life for patients with advanced non-small cell lung cancer, with a clinical symptom improvement rate of 83.5% [2] - In a study on primary liver cancer, the combination of Yangzheng Xiaojie Capsule with interventional chemotherapy resulted in a total effective rate of 65.2%, significantly higher than the control group's 36.1% [2] Group 2: Research and Validation - Research led by Professor Jiang Wenguo from Cardiff University found that Yangzheng Xiaojie Capsule can significantly interfere with tumor cell invasion and metastasis by inhibiting the excessive activation of the PI3K/AKT signaling pathway [1] - The same research also indicated that the capsule inhibits the activity of focal adhesion kinase, thereby suppressing tumor angiogenesis, which contributes to tumor starvation [1] Group 3: Market Expansion - Yangzheng Xiaojie Capsule has recently been approved in Thailand, marking a significant milestone in Yiling Pharmaceutical's internationalization strategy and demonstrating the practical application of traditional Chinese medicine in the "Belt and Road" initiative [4] - Yiling Pharmaceutical has successfully registered 17 innovative traditional Chinese medicines in over 50 countries and regions worldwide, indicating strong international market recognition [4]

Core Viewpoint - The "Eighth Belt and Road Traditional Chinese Medicine Development Forum and the Third OTC Brand Conference" held in Hangzhou aims to promote the development of traditional Chinese medicine (TCM) and OTC brands through international collaboration and standardization, emphasizing the need for safety and effectiveness in TCM practices [2][4][6]. Group 1: Forum Objectives and Contributions - The forum gathered experts, international representatives, and entrepreneurs to provide actionable solutions for TCM development and OTC brand building, fostering high-quality growth in the health industry [2]. - The forum has successfully contributed to integrating TCM into the Belt and Road Initiative, enhancing global health services and improving the well-being of people worldwide [2]. - The emphasis on establishing international standards for TCM and OTC brands is crucial for ensuring quality and safety, which will open more development opportunities [2][6]. Group 2: International Interest and Collaboration - Several foreign diplomats expressed strong interest in TCM development and international cooperation, highlighting the potential for traditional medicine in Africa as an untapped market [4]. - The ambassadors from Malawi and Bahrain noted that the Belt and Road Initiative provides opportunities for TCM research and collaboration, aligning with their national health visions [4]. - The Belarusian ambassador shared local experiences in legalizing TCM and simplifying registration processes to facilitate market entry into Europe, showcasing practical pathways for TCM expansion [8]. Group 3: Industry Standards and Innovation - The president of the China Non-Prescription Drug Association emphasized the mission of high-quality development in the TCM and OTC sectors, advocating for innovation and internationalization of Chinese brands [6]. - The former deputy director of the National Standardization Administration highlighted that standardization is essential for TCM's global integration, urging the industry to use standards as a bridge for innovation [6]. - The forum facilitated policy alignment, standard co-construction, and industry collaboration, providing feasible paths for TCM internationalization and cultural dissemination [10].

Core Viewpoint - The "8th Belt and Road Traditional Chinese Medicine Development Forum and the 3rd OTC Brand Conference" aims to promote the high-quality development of the health industry through dialogue and collaboration among various stakeholders in the OTC and traditional Chinese medicine sectors [1][3]. Group 1: Conference Overview - The conference gathered representatives from "Belt and Road" countries, international organizations, regulatory bodies, industry experts, and media to create a dialogue platform for deep integration in the pharmaceutical and health sectors [3][7]. - The event focused on the innovative development of traditional Chinese medicine and the upgrading of OTC brands, providing actionable paths for brand cultivation and international practices [3]. Group 2: Key Speeches and Insights - The President of the China Non-Prescription Drug Association emphasized the importance of OTC as a vital part of the health service system, advocating for innovation-driven international development of Chinese brands [4]. - The Chairman of the Global Self-Care Federation highlighted China's significant role in strengthening global self-care systems and expressed a willingness to deepen cooperation with Chinese counterparts [4]. - Industry leaders discussed the transformation of consumer health markets and the importance of adapting traditional cultural symbols into globally recognized health values [5]. Group 3: Standards and Initiatives - The conference saw the release of the group standard for "Brand Value Evaluation of Non-Prescription Drug Enterprises," aimed at guiding the development of OTC brands and enhancing overall industry competitiveness [6]. - A new health education project titled "National 'Medicine' Health" was launched, designed to make professional medical knowledge accessible and engaging for the general public [6].

Core Viewpoint - The restructuring of the "National Key Laboratory of Traditional Chinese Medicine Quality" into the "National Key Laboratory of Traditional Chinese Medicine Mechanism and Quality" signifies a strategic shift towards understanding the scientific mechanisms behind traditional Chinese medicine (TCM), particularly its immune regulation capabilities [1][2][3]. Group 1: Research Focus and Direction - The laboratory's new focus on "mechanism" indicates a transition from traditional empirical validation to modern mechanistic explanations, aiming to clarify how TCM works scientifically [3]. - The primary research direction will be the immune regulation mechanisms of TCM, with an ambition to lead global research in this area within 3 to 5 years [2][3]. - The laboratory aims to establish scientific evidence for the mechanisms of TCM, which is essential for quality control and ensuring clinical efficacy and safety [3]. Group 2: Development and Innovation in Macau - Macau's TCM industry is still developing, with a focus on innovative TCM research rather than traditional manufacturing [4]. - The laboratory has multiple research centers that support the development of TCM in Macau, including a center focused on classic formulations expected to enter the market within one to two years [4]. - The establishment of a drug regulatory science research center at the University of Macau will provide quality inspection services for both TCM and Western medicine [4]. Group 3: Talent Recruitment and International Collaboration - The laboratory plans to recruit talent with a background in TCM from developed countries, emphasizing the importance of international scientific education and achievements [7][8]. - There is an openness to non-Chinese scientists joining the team, which is expected to enhance the modernization and internationalization of TCM [7][8]. - The laboratory aims to create an internationalized work environment to attract global talent while also nurturing local talent from Macau [8][9].

Core Viewpoint - The article emphasizes the importance of traditional Chinese medicine (TCM) internationalization through theoretical foundations, scientific innovation, and cultural integration, highlighting Yiling Pharmaceutical's efforts in promoting TCM globally [5][7][9]. Group 1: Theoretical Foundation and Academic Development - Yiling Pharmaceutical has established a comprehensive theoretical framework for "Luo Disease" over 33 years, which is considered a significant milestone in TCM development [5]. - The company has published several authoritative texts on Luo Disease, including "Luo Disease Studies" and "Meridian Theory," which are used in international educational institutions to train TCM professionals [5][6]. - Yiling has created multiple academic exchange platforms globally, including various international associations and conferences, to promote the study and dissemination of Luo Disease theory [6]. Group 2: Market Strategies and Cultural Integration - The company adopts a differentiated market strategy, "one country, one policy," to align with the medical needs and cultural contexts of different regions [7]. - In developed countries, Yiling focuses on high-level clinical research to gain trust from the academic and regulatory communities, while in emerging markets, it integrates products into local healthcare systems [7]. - The successful inclusion of Tongxinluo capsules in Vietnam's medical insurance directory exemplifies the company's effective local integration [7]. Group 3: Evidence-Based Research and International Recognition - Yiling Pharmaceutical has pioneered evidence-based research in TCM since 1995, establishing a robust research system and innovation platform [9][10]. - The company has conducted over 40 high-quality evidence-based studies on its 17 innovative TCM products, with significant findings published in prestigious international medical journals [9][10]. - These studies validate the efficacy and safety of TCM, presenting its wisdom in modern scientific language, thus facilitating international recognition [10]. Group 4: Future Outlook and Challenges - Yiling Pharmaceutical acknowledges the challenges of cultural recognition and regulatory policies in non-Belt and Road countries for TCM's international expansion [12]. - The company believes that collaboration among government, industry, academia, and research institutions is essential to overcome these barriers [12]. - There is confidence that by balancing tradition and innovation, TCM can contribute significantly to global health governance [12].

Core Insights - The "Belt and Road" Traditional Chinese Medicine Development Forum was held in Shanghai, focusing on the cultural dissemination and innovative development of traditional Chinese medicine (TCM) in the context of the Belt and Road Initiative [1] Group 1: Policy and Development - TCM is recognized as a living heritage that contributes significantly to global health systems, emphasizing the need for high-quality development driven by policy, technology, and talent [1] - There is a push for the digital standardization of TCM to align with international standards, facilitating its integration into global health frameworks [1] Group 2: International Collaboration - The forum highlighted the importance of leveraging time-honored brands and food-medicine integration products to promote TCM globally, advocating for localized production to enhance health awareness [1] - The establishment of 30 overseas centers and multilateral mechanisms aims to incorporate TCM into more national public health systems, creating accessible health products along the Belt and Road [1] Group 3: Industry Insights - Discussions at the forum included the international development and collaboration of TCM old brands and the innovative application of the food-medicine integration concept in the modern health industry [1] - Leaders from prominent TCM enterprises shared their experiences and strategies for expanding century-old brands into international markets [1]